A 25-year-old woman presented with a 10-year history of recurrent eruptions on both lower extremities, with exacerbation during the preceding month. Routine blood and urine tests, blood biochemistry, lipid profile, humoral immune indices, and rheumatologic screening showed no obvious abnormalities; antinuclear antibody and the ENA-17 panel were negative, and color Doppler ultrasonography of the bilateral lower-extremity arteries and deep veins was unremarkable. Histopathological examination of the skin revealed fibrinoid necrosis in the superficial dermal vessel walls and intravascular thrombus formation. Livedoid vasculopathy was diagnosed. After treatment with tofacitinib combined with topical Hirudoid and Jinyin Peptide, the lesions healed.
References
[1]
Kumar, A., Sharma, A. and Agarwal, A. (2019) Livedoid Vasculopathy Presenting with Leg Ulcers. Rheumatology, 58, 2076-2076. https://doi.org/10.1093/rheumatology/kez126
[2]
Han, Y. and Tu, P. (2022) Baricitinib Is Potentially Effective in the Treatment of Refractory Livedoid Vasculopathy. FrontiersinImmunology, 13, Article 1008392. https://doi.org/10.3389/fimmu.2022.1008392
[3]
Gao, Y. and Jin, H. (2020) Pathogenesis of Livedoid Vasculopathy. Chinese Journal of Clinical Immunology and Allergy, 14, 479-484. (In Chinese)
[4]
Micieli, R. and Alavi, A. (2018) Treatment for Livedoid Vasculopathy: A Systematic Review. JAMADermatology, 154, 193-202. https://doi.org/10.1001/jamadermatol.2017.4374
[5]
Zhang, H., Watanabe, R., Berry, G.J., Tian, L., Goronzy, J.J. and Weyand, C.M. (2018) Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis. Circulation, 137, 1934-1948. https://doi.org/10.1161/circulationaha.117.030423
[6]
Traves, P.G., Murray, B., Campigotto, F., Galien, R., Meng, A. and Di Paolo, J.A. (2021) JAK Selectivity and the Implications for Clinical Inhibition of Pharmacodynamic Cytokine Signalling by Filgotinib, Upadacitinib, Tofacitinib and Baricitinib. AnnalsoftheRheumaticDiseases, 80, 865-875. https://doi.org/10.1136/annrheumdis-2020-219012
[7]
Jiang, Z., Yao, X., Tang, F., et al. (2023) Experimental Study of the JAK Inhibitor Tofacitinib in the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Journal of Anhui Medical University, 58, 819-823.
[8]
Huang, X., Zheng, H., Wang, M., He, W., Feng, M., Zeng, K., et al. (2022) Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines, 10, Article 549. https://doi.org/10.3390/vaccines10040549
[9]
Bouchnita, A., Miossec, P., Tosenberger, A. and Volpert, V. (2017) Modeling of the Effects of IL-17 and TNF-α on Endothelial Cells and Thrombus Growth. ComptesRendus.Biologies, 340, 456-473. https://doi.org/10.1016/j.crvi.2017.10.002
